QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
OTCMKTS:CYBN

Cybin (CYBN) Stock Price, News & Analysis

$0.35
0.00 (0.00%)
(As of 02/28/2024 ET)
Today's Range
$0.34
$0.37
50-Day Range
$0.29
$0.44
52-Week Range
$0.21
$0.74
Volume
2.77 million shs
Average Volume
3.61 million shs
Market Capitalization
$142.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Cybin MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,056.4% Upside
$7.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.19) to ($0.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.91 out of 5 stars


CYBN stock logo

About Cybin Stock (OTCMKTS:CYBN)

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

CYBN Stock Price History

CYBN Stock News Headlines

Cybin Inc.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cybin Prices Offering Of About 66.67 Mln Units At $0.45/unit
Cybin Inc Ordinary Shares
Small Pharma Obtains Final Order Approving Arrangement
Wall Street Hedge Fund Genius Bets on Cybin Inc.
See More Headlines
Receive CYBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
2/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:CYBN
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+2,056.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-35,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
$0.19 per share

Miscellaneous

Free Float
170,213,000
Market Cap
$142.90 million
Optionable
Not Optionable
Beta
0.44

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Eric So L.L.B. (Age 48)
    Co-Founder, President & Executive Chairman
    Comp: $462.88k
  • Mr. Douglas L. Drysdale (Age 54)
    Chief Executive Officer
    Comp: $618.79k
  • Mr. Paul Glavine (Age 35)
    Co-Founder, Chief Growth Officer & Director
    Comp: $462.88k
  • Mr. Greg Cavers (Age 53)
    Chief Financial Officer
    Comp: $244.2k
  • Mr. Aaron Bartlone
    Chief Operating Officer
  • Mr. John Kanakis (Age 44)
    Co-Founder
    Comp: $710.17k
  • Dr. Alex L. Nivorozhkin Ph.D. (Age 64)
    Chief Scientific Officer
  • Ms. Lori Challenger
    Chief Compliance, Ethics & Administrative Officer
  • Mr. Gabriel Fahel (Age 48)
    Chief Legal Officer & Corporate Secretary
  • Sara Brittany Somerset
    Chief Communications Officers














CYBN Stock Analysis - Frequently Asked Questions

Should I buy or sell Cybin stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYBN shares.
View CYBN analyst ratings
or view top-rated stocks.

What is Cybin's stock price target for 2024?

2 analysts have issued 12 month price targets for Cybin's stock. Their CYBN share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 2,056.4% from the stock's current price.
View analysts price targets for CYBN
or view top-rated stocks among Wall Street analysts.

How have CYBN shares performed in 2024?

Cybin's stock was trading at $0.41 at the start of the year. Since then, CYBN shares have decreased by 15.2% and is now trading at $0.3478.
View the best growth stocks for 2024 here
.

How were Cybin's earnings last quarter?

Cybin Inc. (OTCMKTS:CYBN) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.04.

What ETF holds Cybin's stock ?

Simplify Propel Opportunities ETF holds 500,000 shares of CYBN stock, representing 0.19% of its portfolio.

How do I buy shares of Cybin?

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CYBN) was last updated on 2/28/2024 by MarketBeat.com Staff